The content of mucin MUC-2, -3 and -4 antigens in the bronchial mucosa membrane of chronic obstructive pulmonary disease patients during acute exacerbation — initial report by Kovalenko, Svetlana & Dorofieiev, Andrey
ORIGINAL RESEARCH 
3www.journals.viamedica.pl
Address for correspondence: Svetlana Kovalenko, Bukovinian State Medical University, Ukraine, e-mail: cvetko@ukr.net
DOI: 10.5603/ARM.2017.0002
Received: 03.07.2016
Copyright © 2017 PTChP
ISSN 2451–4934
Svetlana Kovalenko1, Andrey Dorofieiev2 
1Bukovinian State Medical University, Ukraine
2Kiev Nanional Medical University, Ukraine
The content of mucin MUC-2, -3 and -4 antigens in the bronchial 
mucosa membrane of chronic obstructive pulmonary disease 
patients during acute exacerbation — initial report
The authors declare no financial disclosure
Abstract 
Introduction: Changes in mucin production and dyscrinia are common features of inflammation in chronic obstructive pulmonary 
disease (COPD). Immunohistochemical assessment of MUC-2, MUC-3, MUC-4 expression in the integumentary epithelium, goblet 
cells, the epithelium of mucous glands and stroma fusiform cells of the bronchial mucosa of COPD patients during an infectious 
and noninfectious exacerbation was performed. 
Material and methods: 30 patients with stage III COPD were enrolled to the study. Patients were divided into 2 groups: group A — 14 
patients with non-infectious acute exacerbation of COPD (AECOPD) and group B — 16 patients with infectious AECOPD. Fiberoptic bron-
choscopy (FBS) and in vivo bronchial biopsy of bronchial mucosa were implemented to determine the extent and nature of bronchial inflam-
mation. The optical density of specific color in bronchial structures was assessed using immunohistochemical staining to MUC-2, -3 and -4 
antigens by means of primary monoclonal antibodies to these proteins, and visualization system Dako EnVision + System, Peroxidase (AEC). 
Results and conclusions: We detected that in different types of bronchial mucosa epithelial cells, during acute infectious exa-
cerbation, a decrease of antigens MUC-2 and MUC-3 expression of a various degree may occur. This phenomenon in the stroma 
fusiform cells in AECOPD may be a sign of epithelial-mesenchymal transition, that may play a role in the development of an 
inflammatory process and progression of fibrosis in COPD.
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Introduction
There is an evidence that mediators of inflam-
mation may activate mucin gene regulation and 
remodulation of the respiratory tract (RT), inc-
luding cell hyperplasia [1, 2]. Changes in mucin 
production and dyscrinia are common features of 
inflammation in chronic obstructive pulmonary 
disease (COPD), what logically justifies the im-
portance of research on mucins influence in the 
progression of inflammatory processes in RT [3].
 The aim of the study was an assessment of 
mucins MUC-2, -3, and -4 as markers of inflam-
mation in bronchial mucosa in COPD.
Material and methods
Fiberoptic bronchoscopy (FBS) and in vivo 
bronchial biopsy of bronchial mucosa were im-
plemented to determine the extent and nature 
of bronchial inflammation in 30 patients with 
COPD.
 The fresh material was kept for 22 hours in 
neutral buffered aqueous solution of 10% forma-
lin. The specimens were dehydrated in increas-
ing ethanol solutions, and fixed in paraffin. Five 
microns thick — sections were made for further 
assessment. Paraffin sections were mounted onto 
non-immunogenic glass slides (SuperFrost®Plus, 
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Germany). The optical density (in conventional 
units) of specific color in bronchial structures 
were assessed using immunohistochemical stain-
ing to antigens MUC-2, MUC-3 and MUC-4 by 
means of primary monoclonal antibodies to these 
proteins, and visualization system Dako EnVision 
+ System, Peroxidase (AEC). 
 The color intensity (optical density) was 
objectively evaluated in the digital copies of 
micro-preparations optical images, using com-
puter graphics microdencimetry (GIMP software, 
version 2.82, license GPL) by probe method 
gradations in color intensity gradations (from 0 
to 255) with logarithmic recalculation in con-
ventional units of optical density (con.un.opt.
density) from “0” (absolute transparency) to “1” 
(absolute opacity).
 Patients included to the study suffered from 
stage III COPD and were divided into 2 groups: 
group A — 14 patients with clinical signs of ex-
acerbation but without signs of infection (non-in-
fectious AECOPD) and group B — 16 patients 
with infectious exacerbation (infectious AECOPD) 
[1]. In the group A, there were 6 female patients 
(42.8%), 3 active smokers (29.5 ± 2,4 pack-years) 
and 11 ex-smokers. The average FEV1 for the 
group A was 38.9 ± 4.3% of the predicted value. 
In group B, average age was 65.4 ± 4.3 years. 
There were 7 (43.7%) female patients in this 
group. The mean duration of disease was 18.3 
± 1.7 years. There were 5 active smokers and 15 
ex-smokers. The average value of FEV1 for group 
B was 37.6 ± 2.7% of predicted value. All patients 
signed an informed consent before entering the 
study. Institutional ethical commission approved 
the protocol.
 Results
The positive immunohistochemical staining 
for MUC-2 antigen was observed in a few cells that 
were desquamated in the bronchial lumen (Fig. 1). 
The optical density was 0.128 ± 0.010 con.un.opt.
density. Exactly the same quantities were obtained 
for surface bronchial epithelium (Table 1).
The expression of MUC-3 antigen was ob-
served in the bronchial surface epithelium from 
moderate to weak magnitude with average num-
bers of color optical density of 0.201 ± 0.021 
con.un.opt.density. The maximum expression of 
MUC-3 antigen in the bronchial surface epithe-
lium is shown in Figure 3.
 In goblet cells, the MUC-3 antigen expression 
has not been detected. In mucous glands, MUC-3 
Figure 1. Group A — expression of MUC-2 antigen in desquamated 
bronchial epithelium - the immunohistochemical methods of visualiza-
tion with diaminebenzidine. Ob. 20×. Ok.10×
Table 1.  The optical density (in conventional units) of specific immunohistochemical staining of MUC-2, MUC-3, MUC-4 
antigens expression in bronchial structures of patients with COPD (X ± sx)
Immunohistochemical methods/localization Group A 
(n = 14)
Group B  
(n = 16)
Probability of differences (P) 
in the average trend by Mann-
-Whitney method
MUC-2/surface epithelium 0,128 ± 0,010 Not defined p not calculated
MUC-2/goblet cells 0,247 ± 0,016 0,196 ± 0,015 p < 0,05
MUC-2 /epithelium of mucous gland 0,212 ± 0,018 0,103 ± 0,008 p < 0,01
MUC-2/MUC-2- positive spindle cells of stroma 0,208 ± 0,025 0,206 ± 0,028 p > 0,05
MUC-3/surface epithelium 0,201 ± 0,021 0,049 ± 0,006 p < 0,001
MUC-3/goblet cells Not defined Not defined p not calculated
MUC-3/epithelium of mucous gland 0,192 ± 0,009 0,065 ± 0,007 p < 0,001
MUC-3/MUC-3- positive spindle cells of stroma 0,286 ± 0,024 0,289 ± 0,028 p > 0,05
MUC-4/any structure Not defined Not defined p not calculated
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Figure 2. Group A — expression of MUC-2 antigen in the bronchial 
mucous glands epithelium and in spindle (fibroblast) cells of the bron-
chial stroma — immunohistochemical method and visualization with 
diaminebenzidine. Ob. 20×.Ok. 10×
Figure 3. Group A — expression of MUC-3 antigen in the bronchial 
surface epithelium and spindle (fibroblast) cells of the bronchial stroma 
— the immunohistochemical method of visualization with diamineben-
zidine. Ob. 20×.Ok. 10×
Figure 4. Group A — expression of MUC-3 antigen in bronchial mu-
cous glands — the immunohistochemical method of visualization with 
diaminebenzidine. Ob. 20×.Ok. 10×
expression was absent in the majority of cells, 
and in those where it existed (Fig. 4), it could be 
assessed as moderate with average numbers of 
color optical density equal to 0.192 ± 0.009 con.
un.opt.density.
In bronchial stroma, expression of MUC-
3 was determined in the spindle cells under 
sub-epithelial basal membrane (Fig. 3) with the 
moderate to high expression, with average mag-
nitudes of color optical density of 0.286 ± 0.024 
con.un.opt.density.
We observed a  decrease by 75.7% in the 
expression of MUC-3 in bronchial epithelium 
in patients with infectious AECOPD comparing 
to non- infectious one, while in the epithelium 
of mucous glands — by 66.1%. In spindle cells, 
MUC-3 expression did not depend on the nature 
of COPD exacerbation — 0.286 ± 0.024 and 0.289 
± 0.028 (p > 0.05), respectively. In goblet cells, 
MUC-3 expression was not observed in both 
groups of patients.
Discussion
It has been found that during infectious 
AECOPD, in different types of epithelial cells 
of mucous membrane of the bronchial tree, 
a significant decline of MUC-2 and -3 antigens 
expression occurs.
The declined expression of MUC-2 and -3 
antigens in the fusiform cells of the stroma (fibro-
blasts) during a COPD exacerbation may confirm 
an epithelial-mesenchymal transition. Change of 
transformed epithelial cells is a reaction to vario-
us molecular factors which play a certain role in 
the development of an inflammatory process and 
progression of fibrosis in COPD.
In the AECOPD, an expression of secretorial 
MUC-2 and MUC-3 mucins, which contribute to 
the formation of mucus gel component was ob-
served. Synthesis of MUC-2 and MUC-3 decreases 
in infectious exacerbation of stage III COPD com-
pared to their expression in the non-infectious 
exacerbation in all structures except stroma spin-
dle cells — fibroblasts. We believe that reduction 
of mucins expression in infectious AECOPD is 
mostly pronounced in the surface epithelium, 
the epithelium of the mucous glands and less in 
goblet cells. It can be explained by the influence 
of pathogenic microorganisms, which are present 
in a  large amount in the mucous membranes 
and bronchial surface epithelium in infectious 
AECOPD, worsening the composition of normal 
mucus and mucociliary clearance [3]. Uniform 
expression of MUC-2 and -3, which appears in 
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fibroblasts stroma, and does not depend on the 
nature of COPD exacerbation, is hypothetically 
related to epithelial-mesenchymal transition 
(EMT) phenomenon, when normal epithelial cells 
(e.g., mucosal glands) acquire the character of 
miofibroblast cells under the influence of certain 
factors, e.g., TGF-b1 [4]. In EMT, epithelial cells 
which lost intercellular connections, move to the 
interstitium, where after getting full mesenchy-
mal phenotype are involved into the synthesis of 
fibrous matrix [5].
As for MUC-4, it should be noted that in our 
study the expression of this antigen usually has 
not been determined in any structure. Only two 
patients had the expression of MUC-4 antigen 
in the bronchial surface epithelium, and it was 
hardly noticeable.
In group B, MUC-2 antigen expression in the 
surface epithelium is practically not-detectable. 
Thus, during infectious AECOPD, the protein 
production in the surface epithelium seems to be 
impaired. The decreased color intensity of MUC-
2 antigen in the goblet cells and mucous glands 
epithelium are presented in Table 1. Expression 
of MUC-3 antigen in the surface epithelium and 
that of the mucous glands was also decreased 
(Table 1). In goblet cells in infectious, as well as 
in non-infectious AECOPD, expression of MUC-3 
antigen has not been detected.
 Unlike the aforementioned epithelial cells, 
the decrease of expression of MUC-2 and MUC-3 
antigens in spindle cells of bronchial stroma in 
infectious AECOPD has not been found. Thus, 
the formation of these molecules in cells that 
were likely undergone EMT did not change at 
infectious compared to non-infectious AECOPD. 
It may be an evidence, that transformed epithe-
lial cells respond differently to molecular factors 
that influence the development of inflammation 
and progression of fibrosis in COPD than normal 
epithelial cells.
 When the specific staining of the bronchial 
structures for MUC-2, MUC-3, MUC-4 antigens 
was assessed, the expression of various degree 
in surface bronchial epithelium and epithelium 
of the mucous glands, in goblet cells, stroma 
spindle cells (fibroblasts) in infectious and non
-infectious AECOPD was detected. Therefore, in 
the surface of bronchial epithelium, expression 
of MUC-2 was detected in patients without evi-
dence of infectious AECOPD. In the contrary, 
such expression was not observed in infectious 
AECOPD. MUC-2 expression in goblet cells was 
the highest, however it was 31% lower in infectio-
us AECOPD in comparison to non-infectious one. 
MUC-2 expression in the epithelium of mucous 
glands in patients with infectious AECOPD was 
twice less frequent in comparison to patients 
without features of infectious exacerbation. MUC-
2 expression in stromal spindle cells (fibroblasts) 
was observed on the same level of expression in 
the group A and B.
Expression of MUC-4 in bronchial surface 
epithelium was observed only in two patients 
with AECOPD from the group A. This was pro-
bably due to the low sensitivity threshold of the 
method to MUC4 antigen and its weak secretion 
in COPD. The membrane-bound MUC4 presen-
ted in the apical surface of ciliated cells, proba-
bly undergoes desquamation together with the 
epithelium and does not get into the sight of the 
investigated material.
Although the ultimate role of mucins is 
unknown, they can act as receptors or receptor 
ligands and are able to activate intracellular si-
gnaling cascades that affect the functions of the 
epithelial cells, also promoting the development 
of EMT [6, 7].
Conclusions 
Changes in mucins production in the bron-
chial wall may be the sign of inflammation in 
COPD. During infectious AECOPD, in different 
types of epithelial cells of the bronchial mucosa, 
the expression of MUC-2 and MUC-3 antigens de-
creases. Immunohistochemical study of antigens 
MUC-2 and MUC-3 in the stroma spindle cells 
justifies the hypothesis on occurrence of EMT in 
bronchial mucosa in AECOPD.
Study of the functional role of mucins at the 
molecular level is essential for further research 
that will affect the prevention of the progression 
of COPD and its treatment.
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